1 / 10Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has almost completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine even as the company has started developing an Omicron-specific vaccine using the same technology.2 / 10Gennova has developed an mRNA vaccine for the Omicron variant, which will be tested for safety and efficacy for use in humans, a Times of India report said.3 / 10Messenger RNA or mRNA technology involves the injection of a small part of the virus’s genetic code (RNA) to stimulate the recipient’s immune response. 4 / 10It contains instructions for human cells to make proteins that mimic part of the novel coronavirus, spurring the immune system into action. No actual virus is contained in the vaccines.5 / 10The mRNA vaccines were recommended by expert Dr Gagandeep Kang as the best for booster doses. In collaboration with HDT Biotech Corporation, USA, Gennova has developed an mRNA vaccine candidate (HGCO19), with demonstrated safety, immunogenicity, neutralisation antibody activity in the rodent and non-human primate models, a senior government official had told News18.6 / 10Gennova is close to completing phase 3 trials of its Delta variant-based two-dose mRNA after having submitted the phase 2 trial data of over 3000 subjects, the Times of India report said. 7 / 10India’s drug regulator is expected to review the data this week and take a decision regarding approval, the report added.8 / 10“The drug regulator will study and take a decision on whether an approval can be given,” Dr NK Arora, chairman of India’s technical advisory group on Covid vaccination reportedly said.9 / 10The development of an mRNA vaccine is a significant achievement for the country, Dr VK Paul, Covid-19 task force chief was quoted by Times of India as saying. 10 / 10Paul said that the thermos-stable vaccine, using the existing cold-chain infrastructure, and the platform could be useful beyond Covid too.